NasdaqGM - Nasdaq Real Time Price USD

Immutep Limited (IMMP)

2.6700

-0.1800

(-6.32%)

At close: June 7 at 4:00 PM EDT

Immutep successfully completes institutional placement and institutional component of entitlement offer

Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 16 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares in Immutep (New Shares). The Placemen

GlobeNewswire 5 days ago

IMMP
-6.32%
PRRUF
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapyUnder the collaboration, Immutep will conduct the registrational TACTI-004 Phase III trial and MSD will supply KEYTRUDAImmutep retains commercial rights

GlobeNewswire 7 days ago

IMMP
-6.32%
PRRUF
Immutep's (ASX:IMM) investors will be pleased with their notable 73% return over the last five years

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

Simply Wall St. 11 days ago

IMMP
-6.32%
PRRUF
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxelOngoing complete response has been maintained since the patient started treatment with efti monotherapyEfti + paclitaxel combination continues to be well tolerated with a favourable safety profileFirst-ever 90mg dosing leads to higher maximum concentration of efti, as well as pharmacologically active level u

GlobeNewswire 25 days ago

IMMP
-6.32%
PRRUF
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with standard therapiesSoft tissue sarcoma is a hard-to-treat orphan disease with poor prognosis & high unmet medical needAdditional data from EFTISARC-NEO planned for a medical confe

GlobeNewswire last month

IMMP
-6.32%
PRRUF
Immutep Quarterly Activities Report Q3 FY24

Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one patient reporting a complete response (complete disappearance of all lesions), and a 100% disease control rateSubsequent to quarter end announced a positive preliminary response rate of 26.9% in first line metastatic head and neck squamous cell carcinoma patients with negative PD-L1 expressionPreclinical stu

GlobeNewswire last month

IMMP
-6.32%
PRRUF
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?

Wednesday, Immutep Limited (NASDAQ:IMMP) released preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression. The investigational immuno-oncology combination demonstrates an overall response rate (ORR) of 26.9% and diseas

Benzinga last month

IMM.AX
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Media Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9% response rate, the primary endpoint of the studyData collection, cleaning, and analysis continues and additional data from TACTI-003 (Cohorts A & B), including complete response rate, will be released in H1 CY2024 SYDNEY, AUSTRALIA, April 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP

GlobeNewswire last month

IMMP
-6.32%
PRRUF
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune diseasesCHDR will utilize its unique challenge model that enables insights into IMP761’s pharmacological activity early in clinical developmentTrial expected to begin mid-CY2024 SYDNEY, AUSTRALIA, April 18, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ

GlobeNewswire last month

IMMP
-6.32%
PRRUF
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

SYDNEY, AUSTRALIA, April 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received positive feedback from the Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority regarding the Company’s upcoming TACTI-004 Phase III trial of eftilagimod alpha (“efti”) for first line treatment of metastati

GlobeNewswire last month

IMMP
-6.32%
PRRUF
Immutep Limited (ASX:IMM): Is Breakeven Near?

Immutep Limited ( ASX:IMM ) is possibly approaching a major achievement in its business, so we would like to shine some...

Simply Wall St. 2 months ago

IMM.AX
11 Best ASX Stocks To Buy Now

In this piece, we will take a look at the 11 best ASX stocks to buy now. If you want to skip our introduction to the Australian stock market, then you can take a look at the 5 Best ASX Stocks To Buy Now. With a market capitalization of $1.5 trillion, the Australian stock exchange, […]

Insider Monkey 2 months ago

ASXFY

BHP

RIO
Immutep Announces First Clinical Data from 90mg Dosing of Efti

Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEncouraging initial efficacy in six metastatic breast cancer patients, who exhausted all endocrine therapy including CDK4/6 inhibitors, demonstrated by a 50% overall response rate, including one complete response, and a 100% disease control rate SYDNEY, AUSTRALIA, March 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a cl

GlobeNewswire 3 months ago

IMMP
-6.32%
PRRUF
Individual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%

Key Insights Immutep's significant individual investors ownership suggests that the key decisions are influenced by...

Simply Wall St. 3 months ago

IMM.AX
10 Best Australian Stocks To Buy

In this piece, we will take a look at the ten best Australian stocks to buy. If you want to skip our coverage of some of the biggest stocks in Australia and how you might trade them, then you can skip ahead to 5 Best Australian Stocks To Buy. When we talk about the fundamentals […]

Insider Monkey 4 months ago

BHP

RIO

TEAM
Immutep Quarterly Activities Report Q2 FY24

Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS ≥1%)Promising efficacy and tolerability data reported from INSIGHT-003 Phase I trial, including a strong Overall Response Rate of 71.4% in 1L NSCLC patientsLate-stage & registrational trial progress: 1L NSCLC: constructive regulatory feedback received for registrational TACTI-004 Phase III

GlobeNewswire 4 months ago

IMMP
-6.32%
PRRUF
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Media Release SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial. The investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate eftilagimod alpha (“efti”) in combination

GlobeNewswire 5 months ago

IMMP
-6.32%
PRRUF
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Media Release SYDNEY, AUSTRALIA, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces constructive feedback has been received from the Paul-Ehrlich-Institut (“PEI”), a German regulatory authority and part of the Committee for Medicinal Products for Human Use (CHMP), regarding the planned TACTI-004 Phase III trial of e

GlobeNewswire 5 months ago

IMMP
-6.32%
PRRUF
Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Media Release SYDNEY, AUSTRALIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The “Crédit d’Impôt Recherche” (CIR), me

GlobeNewswire 5 months ago

IMMP
-6.32%
PRRUF
Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years ago

For many, the main point of investing is to generate higher returns than the overall market. But even the best stock...

Simply Wall St. 6 months ago

IMM.AX

Performance Overview

Return	IMMP	S&P/ASX 200 [XJO]
YTD	+11.25%	+3.55%
1-Year	+22.48%	+10.42%
3-Year	-46.28%	+7.94%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immutep Limited (IMMP)

Immutep successfully completes institutional placement and institutional component of entitlement offer

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep's (ASX:IMM) investors will be pleased with their notable 73% return over the last five years

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep Quarterly Activities Report Q3 FY24

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited (ASX:IMM): Is Breakeven Near?

11 Best ASX Stocks To Buy Now

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Individual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%

10 Best Australian Stocks To Buy

Immutep Quarterly Activities Report Q2 FY24

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years ago

Performance Overview